Catalys Pacific and SR One, two significant life science investment firms with a presence across the Pacific and Atlantic, have jointly announced the formation of Renalys Pharma, Inc. This clinical-stage biopharmaceutical company is dedicated to developing treatments for individuals with renal disease, particularly focusing on Japan and selected Asian countries.
Renalys Pharma is committed to advancing sparsentan, an investigational dual-acting treatment developed by Travere Therapeutics, for patients with IgA nephropathy in Japan and specific Asian countries. Sparsentan, known in the US as FILSPARI®, functions as a dual endothelin and angiotensin receptor antagonist, offering a distinctive approach to IgA nephropathy treatment. Preclinical data indicates its efficacy in reducing proteinuria, protecting podocytes, and impeding the progression of kidney disease.
After successful consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Renalys Pharma plans to initiate an open-label registrational study of sparsentan in Japan in Q2 2024. Leveraging global pivotal studies conducted earlier, the company aims to support potential sparsentan approval in Japan. Anticipated results from the study's UP/C endpoint in the second half of 2025 will contribute to the submission for PMDA approval. Sparsentan, as a non-immunosuppressive therapeutic, holds promise in safeguarding kidney function for a significant patient population.
Under the leadership of CEO BT Slingsby, Renalys Pharma emphasizes the importance of global collaboration in biopharma, aiming to forge cross-sectional partnerships and leverage new technologies to improve the lives of those with renal disease. The company adopts a patient-first approach, striving to offer comprehensive support for patients to lead fulfilling lives.
Supported by venture capital leaders Catalys Pacific and SR One, Renalys Pharma combines the expertise of both firms to advance renal disease treatments. The company has attracted top talent in renal drug development and commercialization, primarily from former executives of Kyowa Kirin, known for launching groundbreaking renal therapies.
Catalys Pacific, with a history of building transpacific life sciences companies, has contributed to the establishment of Renalys Pharma. The collaboration between Renalys Pharma, Catalys Pacific, and SR One reflects the global nature of biopharmaceutical cooperation. With end-to-end support from research to commercialization, Renalys Pharma is well-positioned to accelerate the development of innovative renal disease therapies. This international collaboration underscores the boundary-free essence of transformative scientific endeavors.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!